The first patient has been dosed in a phase 2 clinical trial for SURF-200 investigating treatment for acute dry eye, according to a press release from Surface Ophthalmics.
Two low-concentration formulations of betamethasone in Klarity vehicle are under study in the dose-ranging trial that will enroll between 120 and 140 patients. Primary endpoint is symptom improvement measured at day 8, according to the release.
“With a proven diluent designed to protect the ocular surface and a potent corticosteroid, I’m hopeful that SURF-200 will provide a much-needed treatment option,”
Uncategorized